Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 60,000 shares at $98.96 ($6.3M) on 2026-08-17, disclosed to the SEC on 2026-08-19.
Scheduled sale ($6.3M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $98.96 | 900 | $89K | 1.4% |
| 2 | $100.46 | 500 | $50K | 0.8% |
| 3 | $101.77 | 2,100 | $214K | 3.4% |
| 4 | $102.55 | 9,000 | $923K | 14.7% |
| 5 | $103.48 | 7,500 | $776K | 12.4% |
| 6 | $103.08 | 5,703 |
| $588K |
| 9.4% |
| 7 | $104.11 | 4,897 | $510K | 8.1% |
| 8 | $104.87 | 9,400 | $986K | 15.7% |
| 9 | $106.36 | 7,200 | $766K | 12.2% |
| 10 | $107.22 | 9,600 | $1.0M | 16.4% |
| 11 | $107.77 | 3,200 | $345K | 5.5% |
| Total | $104.59 avg | 60,000 | $6.3M | 100% |
| Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |
| HALO | SELL | 2026-05-13 | $3.4M | — | Filing → |